We Found our First Unicorn Stock

Unicorn Portfolio Update 5: #8 of 20 stocks added

ClearPoint Neuro: The brain delivery platform for the future

One of the biggest challenges in neuro-related diseases is the delivery mechanism of the chosen therapy. The brain is a highly complex system and navigating inside it requires the utmost precision. This micro-cap company believes they have developed the solution. ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Their platform already has FDA clearance, which reduces some of the risks and they are growing their TAM by expanding into multiple markets. We will dive deeper into this life-changing company in a future article. With a score of 80, it is the first company to achieve Unicorn status on our Unicorn Portfolio Scorecard.

Portfolio Update Summary

• Buy $500 CLPT at $8.60

Disclosure

This is not financial advice and is based on the author's opinion. The $10K is not real money and only a demonstration of a typical portfolio. The Unicorn Portfolio is a high-risk portfolio and should always remain a small allocation of your overall assets. This is an actively managed portfolio where we will buy and sell positions as we deem fit without any regard for taxation. Remember, all selling of stocks triggers a tax event in most countries and it is the investors personal responsibility to always remain tax compliant.